Research & Literature

Bone marrow and splenic histology in hairy cell leukaemia.

Wotherspoon A, Attygalle A, Mendes LS

Best practice & research. Clinical haematology 2015; (28(4)):200-7.

Hairy Cell Leukemia and Bone Pain.

Streu E

Oncology nursing forum 2016; (43(1)):18-21 doi:10.1188/16.ONF.18-21.

Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant.

Mason EF, Brown RD, Szeto DP, et al.

Leukemia & lymphoma 2017; (58(1)):233-236 doi:10.1080/10428194.2016.1185786.

BRAF inhibitor: targeted therapy in hairy cell leukemia.

Grever MR

Blood 2016; (127(23)):2784-5 doi:10.1182/blood-2016-03-704262.

Genomics of Hairy Cell Leukemia.

Tiacci E, Pettirossi V, Schiavoni G, Falini B

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(9)):1002-1010 doi:10.1200/JCO.2016.71.1556.

Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in The Netherlands.

Dinmohamed AG, Posthuma EFM, Visser O, et al.

Blood 2018; (131(12)):1380-1383 doi:10.1182/blood-2017-12-820381.

Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience.

Angelova EA, Medeiros LJ, Wang W, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018; (31(11)):1717-1732 doi:10.1038/s41379-018-0093-8.

Outcome of hairy cell leukemia patients treated with cladribine - a 10-year single-center experience in Pakistan.

Zahid MF, Mehdi MQ, Ali N

Hematology, transfusion and cell therapy 2019; (41(2)):134-138 doi:10.1016/j.htct.2018.08.006.

Expression of the muscle-associated gene MYF6 in hairy cell leukemia.

Arons E, Zhou H, Sokolsky M, et al.

PloS one 2020; (15(2)):e0227586 doi:10.1371/journal.pone.0227586.

Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.

Paillassa J, Cornet E, Noel S, et al.

Blood cancer journal 2020; (10(5)):62 doi:10.1038/s41408-020-0328-z.

Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.

Benz R, Arn K, Andres M, et al.

Blood advances 2020; (4(15)):3699-3707 doi:10.1182/bloodadvances.2020002160.

Treatment of hairy cell leukemia.

Chihara D, Kreitman RJ

Expert review of hematology 2020; (13(10)):1107-1117 doi:10.1080/17474086.2020.1819231.

Lytic Bone Lesion: An Unusual Presentation of Hairy Cell Leukemia.

Fasulo SM, Narvaneni S, Kumar V, et al.

Cureus 2021; (13(1)):e12959 doi:10.7759/cureus.12959.

Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.

Tiacci E, De Carolis L, Simonetti E, et al.

Leukemia 2021; (35(11)):3314-3318 doi:10.1038/s41375-021-01210-8.

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.

Grever M, Andritsos L, Banerji V, et al.

Leukemia 2021; (35(7)):1864-1872 doi:10.1038/s41375-021-01257-7.

Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox.

Robak T, Janus A, Jamroziak K, et al.

Journal of clinical medicine 2021; (10(13)) doi:10.3390/jcm10132800.

Hairy Cell Leukemia Masquerading as CD5+ Lymphoproliferative Disease: The Importance of BRAF V600E Testing in Diagnosis and Treatment.

Soong D, Kumar P, Jatwani K, et al.

JCO precision oncology 2021; (5()) doi:10.1200/PO.20.00518.

Patients with relapsed/refractory hairy-cell leukemia.

Paillassa J, Troussard X

Cancer reports (Hoboken, N.J.) 2022; (5(3)):e1495 doi:10.1002/cnr2.1495.

Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.

Troussard X, Maître E, Cornet E

American journal of hematology 2022; (97(2)):226-236 doi:10.1002/ajh.26390.

Classic hairy cell leukemia with an aggressive presentation.

Fugere T, Harley S, Godbole A

Proceedings (Baylor University. Medical Center) 2021; (34(6)):721-723 doi:10.1080/08998280.2021.1934344.

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia.

Broccoli A, Argnani L, Cross M, et al.

Blood advances 2022; (6(14)):4224-4227 doi:10.1182/bloodadvances.2022007854.

Long-term follow-up of patients with hairy cell leukemia in the south of Iran.

Dehghani M, Kashkooe A, Namdari N, et al.

Expert review of hematology 2023; (16(4)):289-295 doi:10.1080/17474086.2023.2174520.

Almost a Near Miss: Hairy Cell Leukemia.

Parkash J, Bansro V, Chhabra GS, Mujahid Z

Cureus 2023; (15(1)):e33949 doi:10.7759/cureus.33949.

[Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant].

Wei C, Jin XX, Cai H, et al.

Zhonghua nei ke za zhi 2023; (62(4)):416-421 doi:10.3760/cma.j.cn112138-20220414-00274.

Hairy cell leukaemia with unusual BRAF mutations.

Maitre E, Macro M, Troussard X

Journal of cellular and molecular medicine 2023; (27(17)):2626-2630 doi:10.1111/jcmm.17890.

Untangling the Strands of Hairy Cell Leukemia: The Clinicopathological Spectrum over Eleven Years at a Tertiary Care Center.

Rai V, Manimaran P, Saha A, et al.

Discoveries (Craiova, Romania) 2023; (11(2)):e166 doi:10.15190/d.2023.5.

Single-center study of outcomes of patients with hairy cell leukemia who contracted SARS-CoV-2.

Annunzio K, Ozga M, Huang Y, et al.

EJHaem 2023; (4(4)):1200-1202 doi:10.1002/jha2.764.

Hairy Cell Leukemia (HCL) Presenting As Severe Acute Respiratory Distress Syndrome (ARDS) With Legionella pneumophila: Coincidence or Causation?

Holloway KD, Amisha F, Post G, Goraya H

Cureus 2023; (15(11)):e48317 doi:10.7759/cureus.48317.

Untangling hairy cell leukaemia (HCL) variant and other HCL-like disorders: Diagnosis and treatment.

Troussard X, Maitre E

Journal of cellular and molecular medicine 2024; (28(3)):e18060 doi:10.1111/jcmm.18060.

New Targeted Therapy Combination Holds Promise to Untangle Hairy Cell Leukemia.

Soong D, Taylor J

NEJM evidence 2023; (2(10)):EVIDe2300173 doi:10.1056/EVIDe2300173.

Clinical analysis of hairy cell leukemia: the rare indolent hematological malignancy.

Huang H, Liu Y, Zeng M, et al.

American journal of translational research 2024; (16(2)):466-476.

Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.

Yiğit Kaya S, Mutlu YG, Malkan ÜY, et al.

Leukemia research 2024; (140()):107495 doi:10.1016/j.leukres.2024.107495.

Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.

Marvin-Peek J, Jen WY, Kantarjian HM, et al.

Leukemia & lymphoma 2024; (65(9)):1325-1334 doi:10.1080/10428194.2024.2349700.

Concomitantly Diagnosed Disseminated M kansasii Infection and Hairy Cell Leukemia With Review of Pathophysiology.

Stanton DJ, Quadri NZ, Tanabe MB

Journal of investigative medicine high impact case reports 2024; (12()):23247096241253343 doi:10.1177/23247096241253343.

Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group.

Paillassa J, Maitre E, Belarbi Boudjerra N, et al.

Cancers 2024; (16(12)) doi:10.3390/cancers16122185.

Hairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions.

Troussard X

Expert review of hematology 2024; (17(12)):907-915 doi:10.1080/17474086.2024.2427660.

CD103-Negative Hairy Cell Leukemia: A Case Report From University Teaching Hospital, Zambia.

Kaweme NM, Butress SMN, Akekelwa I, et al.

Case reports in medicine 2025; (2025()):7084757 doi:10.1155/carm/7084757.

Hairy Cell Leukemia Diagnosed by Flow Cytometry Despite Absence of Hairy Cells in Peripheral Blood: A Case Report.

Nakano K, Fukatsu Y, Oka S, Takahashi T

Cureus 2025; (17(7)):e88536 doi:10.7759/cureus.88536.

Expert consensus opinion on the management of hairy cell leukemia in elderly patients.

Tadmor T, Demeter J, Fagarasanu A, et al.

Leukemia & lymphoma 2025; (66(14)):2611-2617 doi:10.1080/10428194.2025.2562961.